GUARDIAN registry data was analyzed to evaluate post-operative cost differences from improvements in clinical outcomes and their associated reductions in clinical interventions1
[.c-text-4]1) Voight et al., ASAIO Journal 2022[.c-text-4]
Improved 2-Year Heart Transplant Survival with Moderate Hypothermic Donor Heart Preservation
[.c-text-4] S. Silvestry, D. Meyer, S. Pham, J. Jacobs, Y. Shudo, J. Schroder, M. Leacche, C. Sciortino, H. Copeland, M. Rodrigo, K. Takeda, M. Kawabori, B. Mahesh, L. Klein, A. Vidic, S. Patel, D. D’Alessandro[.c-text-4]
[.c-text-4] ISHLT 2024 Presentation[.c-text-4]
Investigators found that 2-year post transplant survival in matched cohorts (from 89% to 95%, p=0.04) is superior in the SherpaPak cohort1. This survival benefit is potentially due to reduced the incidence of severe PGD (from 11% vs 5.5%, p=0.01) and reduced need for mechanical circulatory support after transplant1. The study concluded that Advanced hypothermic preservation of the donor heart should be strongly considered as an important factor contributing to a center’s post transplant and 2-year outcomes.1
[.c-text-4]1) Silvestry et al., ISHLT Presentation 2024, Data on file[.c-text-4]
Comparison of Paragonix SherpaPak to Ice Storage, Paragonix data on file. GUARDIAN is a registered clinical study (NCT04141605) funded and administered by Paragonix Technologies. The data from the registry is descriptive, not statistically powered, and not pre-specified. The information should be interpreted accordingly.